New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases

Mei‐Sing Ong(Boston Children's Hospital), Marc D. Natter(Boston Children's Hospital), Mary Beth F. Son(Boston Children's Hospital), Sara Barmettler(Massachusetts General Hospital), Mindy S. Lo(Boston Children's Hospital), Jordan E. Roberts, Deborah Rothman(Harvard University Press)
Lara D. Veeken
July 29, 2021
10.1093/rheumatology/keab626
Cited by 19

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
|Arthritis & Rheumatology|2020|415